Ascletis Pharma Inc. (Ascletis-B, 01672) has adopted its Third Amended and Restated Memorandum and Articles of Association, effective 29 June 2026, following shareholder approval by special resolution. Key corporate governance and capital structure changes are outlined below:
• Capital Structure – Authorised share capital is confirmed at US$700,000, divided into 7.00 billion ordinary shares with a par value of US$0.0001 each. – The Board retains broad authority to issue new shares, create classes with varied rights, and implement share buy-backs or redemptions, subject to Hong Kong Listing Rules.
• Shareholder Meeting Flexibility – Annual general meetings must be held within six months of each financial year-end. – The revised Articles formally allow physical, hybrid and fully electronic general meetings, with shareholders attending either in person or via approved electronic platforms. – For electronic or hybrid meetings, shareholders participating online are counted in quorum and can vote in real time.
• Director Tenure and Governance Enhancements – The Board must consist of at least two directors; one-third retire by rotation at each AGM, ensuring every director faces re-election at least once every three years. – The Articles remove any mandatory retirement age for directors and allow removal by ordinary resolution. – Directors are prohibited from voting on board resolutions in which they or close associates have a material interest, aligning with Hong Kong listing requirements.
• Capital Management Tools – Provisions enable capitalisation of reserves for bonus share issues and provide mechanisms for scrip dividends, allowing shareholders to elect stock or cash. – The company may pay dividends in any currency and retain unclaimed dividends for six years before forfeiture.
• Administrative Provisions – Notices and corporate documents can be distributed by electronic means or published on designated websites, reducing reliance on physical mail. – Updated procedures cover untraceable shareholders, permitting disposal of shares after 12 years of returned dividends and no contact.
These amendments modernise Ascletis’s corporate framework, aligning it with current Cayman Islands law and Hong Kong Listing Rules while providing greater flexibility in capital management and shareholder engagement.
Comments